Amarin Corp Plc (AMRN)

[ralphey]

V = 3500 new Rx's
L = 2600

Assuming VHT is only 10% of the RX;s one has to come to the conclusion that either

1.) LOvaza is penetrating the market for their 10% indication much more thoroughly than AMRN's penetration of a market that is easily 10 x larger. Yet there is no advertising that I see for Lovaza for trigs > 500 this is old information and not being actively pursued by any pharmaceutical firm that I am aware of or

2.) Lovaza is being prescribed for a CAD indication - a reflection on AMRN's poor job of education and intervention

gv = 1600 New Rx's

Once again

1.) gV is penetrating the market for VHT much better than V for CAD ? - yet how can this be - they perform no marketing -

2.) gV is directly infringing on the CAD market

WE can clearly say that 90% of AMRN's RX are for CAD indication.


gV has 1600 RX's - theoretically only for VHT with no advertising. AMRN then with no advertising but a 90% greater market V should have 14,400 new Rx's

Since gV has never performed any advertising for the VHT market - their only indication - how can one say that with no advertising gV penetrates the VHT market substantially more then AMRN penetrates the CAD market with some advertising ?